Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005760-42
    Sponsor's Protocol Code Number:MBGS205
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-04-14
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-005760-42
    A.3Full title of the trial
    A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism
    Estudio de fase IIb, aleatorizado, multicéntrico, doble ciego, de búsqueda de dosis y controlado con placebo para evaluar la seguridad y eficacia de BGS649 en varones obesos con hipogonadismo hipogonadotrópico
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A trial to determine the how safe and effective the test drug is for obese males with hypogonadotropic hypogonadism. The trial is blinded and the subjects may be given the test drug or a placebo.
    Un ensayo para determinar la seguridad y la eficacia del fármaco de ensayo en varones obesos con hipogonadismo hipogonadotrópico. El ensayo es ciego y los pacientes podrán recibir el fármaco del ensayo o un placebo.
    A.4.1Sponsor's protocol code numberMBGS205
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMereo BioPharma 2 Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMereo BioPharma 2 Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationICON Clinical Research
    B.5.2Functional name of contact pointProject management
    B.5.3 Address:
    B.5.3.1Street Address79 T.W. Alexander Drive , 4401 Research Commons Bldg Suite 300, PO Box 1435
    B.5.3.2Town/ cityDurham, NC
    B.5.3.3Post code27709 - 4353
    B.5.3.4CountryUnited States
    B.5.4Telephone number+34911916197
    B.5.6E-mailCharles.Hayward@iconplc.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BGS649
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot established
    D.3.9.1CAS number 143030-47-1
    D.3.9.2Current sponsor codeBGS649
    D.3.9.3Other descriptive nameFluor-DCP-triazol
    D.3.9.4EV Substance CodeSUB121119
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BGS649
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot established
    D.3.9.1CAS number 143030-47-1
    D.3.9.2Current sponsor codeBGS649
    D.3.9.3Other descriptive nameFluor-DCP-triazol
    D.3.9.4EV Substance CodeSUB121119
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1.0
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hypogonadotropic hypogonadism (HH)
    hipogonadismo hipogonadotrópico (HH)
    E.1.1.1Medical condition in easily understood language
    Hypogonadotropic hypogonadism (HH) is a gonadotropin-releasing hormone deficiency which may cause obesity, low libido and infertility.
    El hipogonadismo hipogonadotrópico (HH) es una deficiencia de la hormona liberadora de gonadotropina que puede causar obesidad, disminución de la libido e infertilidad.
    E.1.1.2Therapeutic area Body processes [G] - Reproductive physiologi cal processes [G08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10021012
    E.1.2Term Hypogonadotrophic hypogonadism
    E.1.2System Organ Class 100000004860
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to demonstrate the efficacy of BGS649 to normalise total testosterone levels (300-1000 ng/dL [10.4-35 nmol/L]) in ? 75% of subjects after 24 weeks of treatment.
    El objetivo principal es demostrar la eficacia de BGS649 para normalizar los niveles totales de testosterona (300 1000 ng/dl [10,4 35 nmol/l]) en >=75 % de los pacientes al cabo de 24 semanas de tratamiento
    E.2.2Secondary objectives of the trial
    Secondary Objectives
    1. To follow the time-course of normalisation in total testosterone levels
    2. To demonstrate the efficacy of BGS649 to normalise total testosterone levels in ? 90% of subjects after 24 weeks of treatment
    3. To evaluate the effect of BGS649 on luteinising hormone (LH) and follicle stimulating hormone (FSH)
    4. To further determine the pharmacokinetics (PK) of BGS649.

    Safety Objectives:
    1. To evaluate safety and tolerability of BGS649.

    Exploratory Objectives:
    1. To evaluate the effect of BGS649 on oestradiol and inhibins (A and B)
    2. To evaluate the effect of BGS649 on testosterone/oestradiol ratio
    3. To investigate patient reported outcomes (PROs) following treatment with BGS649. Evaluated PROs will
    include:
    - Sexual function (International Index of Erectile Function [IIEF])
    - Energy/fatigue (Brief Fatigue Inventory [BFI])
    - SF-36 Quality of life (QoL) questionnaire

    For additional Exploratory Objectives refer to the protocol
    Objetivos secundarios
    1. Seguir evolución temporal de la normalización de niveles totales de testosterona.
    2. Demostrar la eficacia de BGS649 a la hora de normalizar los niveles totales de testosterona en >=90 % de los pacientes al cabo de 24 semanas de tratamiento.
    3. Evaluar efecto de BGS649 sobre hormona luteinizante (LH) y hormona foliculoestimulante (FSH).
    4. Determinar mejor la farmacocinética (FC) de BGS649.
    Objetivos seguridad
    1. Evaluar seguridad y tolerabilidad de BGS649.
    Objetivos exploratorios
    1. Evaluar efecto de BGS649 sobre estradiol e inhibinas (A y B).
    2.Evaluar efecto de BGS649 sobre tasa testosterona/estradiol.
    3.Investigar resultados notificados por pacientes (RNP) tras tratamiento con BGS649. Los RNP incluirán:
    -Actividad sexual (según Índice Internacional Función Eréctil [IIEF]).
    -Energía/astenia (según cuestionario breve sobre astenia [BFI]).
    -Cuestionario SF-36 sobre calidad de vida (CdV).
    Ver protocolo para Objetivos exploratorios adicionales.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adult male subject aged 18 to 65 years inclusive
    2. BMI > 30 kg/m2 and < 50 kg/m2
    3. Serum total testosterone concentration below the normal range (serum total testosterone < 300 ng/dL [< 10.4 nmol/L]) based on an average of two morning samples taken at least 3 days apart
    4. LH levels below the upper limit of normal (ULN)
    5. Oestradiol levels within or above the normal range of approved assay
    6. At least two symptoms of androgen deficiency present for at least 2 months prior to the first Screening Visit, with at least one of these being a sexual dysfunction
    7. Agreement on the part of the subjects to use double-barrier contraception and refrain from sperm donation for the duration of the study and for at least 3 months following study drug discontinuation
    8. Ability to understand and comply with the requirements of the protocol/study, including understanding and being able to give informed consent.
    1.Pacientes varones adultos con edades comprendidas entre los 18 y los 65 años, inclusive.
    2.IMC >30 kg/m2 y <50 kg/m2.
    3.Concentración de testosterona total en suero inferior al intervalo normal (testosterona total en suero <300 ng/dl [<10,4 nmol/l]) a partir de una media de dos muestras matutinas recogidas con al menos 3 días de diferencia.
    4.Niveles de LH inferiores al límite superior de la normalidad (LSN).
    5.Niveles de estradiol dentro del intervalo normal de análisis autorizado o superiores.
    6.Al menos dos síntomas de deficiencia de andrógenos presentes durante un mínimo de 2 meses antes de la primera visita de selección, y que al menos uno de ellos sea una disfunción sexual.
    7. Aceptación por parte de los pacientes de utilizar un método anticonceptivo de doble barrera y abstenerse de donar esperma mientras dure el estudio y, como mínimo, 3 meses después de interrumpir el tratamiento con el fármaco del estudio.
    8.Capacidad de comprender y cumplir los requisitos del protocolo/estudio, incluida la comprensión y aceptación del consentimiento informado
    E.4Principal exclusion criteria
    1. Evidence of clinically significant endocrinopathy at Screening that may interfere with the study assessments or mask/mimic symptoms of hypogonadism e.g., growth hormone deficiency, adrenal deficiency, untreated hypothyroidism (primary hypothyroidism on replacement with normal thyroid stimulating hormone [TSH] level is allowed), or that may interfere with the evaluation of efficacy/safety parameters
    2. Other types of HH (e.g., Kallmann syndrome) or primary hypogonadism (e.g., cryptorchidism, or Klinefelter syndrome)
    3. Any other pituitary or hypothalamic disease, as based on one of the following:
    - Current or past hypothalamic or pituitary tumour
    - Suspicion of pituitary or hypothalamic tumour based on a clinical or laboratory evidence, e.g., elevated prolactin or other pituitary hormone abnormality, symptoms/signs of tumour mass effect, very low testosterone and LH (unless there is documentation of a normal magnetic resonance imaging scan of pituitary and hypothalamus within 3 months before first Screening Visit)
    - Hypothalamic or pituitary conditions, which may contribute to hypogonadism e.g., pituitary sarcoidosis, histiocytosis or tuberculosis
    4. Subject with prostate disease, as confirmed by the presence of one of the following:
    - History of prostate cancer
    - Elevated PSA levels ? 3 ng/mL at Screening
    - Subjects with a detectable prostate nodule or induration at Screening unless proven previously benign by a biopsy
    - Urologist confirmed symptomatic benign prostatic hyperplasia
    5. History of type 1 diabetes mellitus
    6. Current diagnosis of clinical depression or depressive disorder
    7. Uncontrolled type 2 diabetes mellitus (HbA1c > 8.5% at Screening) or significant diabetic neuropathy. Subjects with type 2 diabetes can be included when both of the following conditions are met:
    - Having adequately controlled glucose, with HbA1c ? 8.5% at Screening, and:
    - Anti-diabetic medication regimen (excluding insulin) has been stable for ? 8 weeks before the first Screening visit
    8. Treatment with one or more of the following prescribed or over the counter medications in the six months prior to first Screening Visit:
    - Medication with androgenic or estrogenic properties or that affect production of sex hormones
    - Other testosterone enhancement therapy
    - Fertility drugs
    - Growth hormone
    - Anabolic steroids
    - Monoclonal antibodies
    9. Treatment with one of the following medications in the three months prior to first Screening Visit:
    - Testosterone lowering drugs e.g., spironolactone, cimetidine, 5?-reductase inhibitors
    - Opiates including methadone
    - Medications known to increase prolactin levels, e.g., antipsychotics
    - Insulin
    10. Treatment with the following medications:
    - Chronic systemic steroid treatment or systemic steroids for > 5 consecutive days for intercurrent illness within the 4 weeks prior to the first Screening visit (inhaled and topical steroids are allowed)
    - New prescription or over-the-counter drug known to affect glucose homeostasis within the 4 weeks prior to first Screening Visit
    - Clomid within 1 year before first Screening Visit
    - Biphosphonates or other medication used to treat low bone density (denosumab, teriparatide) except calcium and vitamin D within 1 year before first Screening Visit
    11. Weight loss or weight gain (gain or loss of up to 5% body weight) within the 3 months prior to first Screening Visit
    12. Participation in any clinical trial using clinical intervention within 3 months before first Screening Visit or 5 half-lives of investigational product administration, whichever is shorter
    13. Any clinically significant 12-lead ECG abnormalities at Screening including corrected QT interval by Fridericia?s correction method (QTCF) > 450 ms
    14. Medical history of Long QT syndrome
    15. History of thromboembolic disease
    16. Grade 3 lower extremity oedema
    17. Use of cardiac pacemaker or other medical electronic devices that can be affected by bioimpedance assessment

    Refer to the protocol for additional exclusion criteria
    1. Evidencia de endocrinopatía clínicamente significativa durante la selección que pueda interferir con las evaluaciones del estudio o enmascarar/imitar los síntomas del hipogonadismo: p. ej., deficiencia de la hormona del crecimiento, insuficiencia suprarrenal, hipotiroidismo no tratado (está permitido el hipotiroidismo primario en sustitución con niveles normales de tirotropina [TSH]); o bien, que pueda interferir con la evaluación de los parámetros de eficacia o seguridad.
    2. Otros tipos de HH (p. ej., síndrome de Kallmann) o hipogonadismo primario (p. ej., criptorquidia o síndrome de Klinefelter).
    3. Cualquier otro trastorno hipotalámico o pituitario, conforme a uno de los siguientes:
    -Tumor pituitario o hipotalámico actual o pasado.
    -Sospecha de tumor pituitario o hipotalámico a la vista de los resultados clínicos o analíticos: p. ej., prolactina elevada u otra anomalía pituitaria hormonal, síntomas/signos de efecto de masa tumoral, testosterona y LH muy bajas (a menos que se disponga de documentación consistente en una prueba de resonancia magnética normal de la hipófisis y el hipotálamo en los 3 meses previos a la primera visita de selección).
    -Afecciones pituitarias o hipotalámicas, que puedan contribuir al hipogonadismo (p. ej., sarcoidosis hipofisaria, histiocitosis o tuberculosis).
    4. Paciente con enfermedad prostática, confirmada por la presencia de alguno de los siguientes factores:
    -Antecedentes de cáncer de próstata.
    -Niveles elevados de PSA >=3 ng/mL en la selección.
    -Pacientes que presenten una induración o un nódulo prostático detectable en la selección, a menos que se haya demostrado anteriormente su benignidad mediante una biopsia.
    -Hiperplasia prostática benigna y sintomática confirmada por un urólogo.
    5. Antecedentes de diabetes mellitus de tipo 1.
    6. Diagnóstico actual de depresión mayor o trastorno depresivo.
    7. Diabetes mellitus de tipo 2 no controlada (HbA1c >8,5 % durante la selección) o neuropatía diabética de importancia. Podrá incluirse a los pacientes que presenten diabetes de tipo 2 si se cumplen las dos condiciones siguientes:
    -Tener la glucosa bien controlada, con HbA1c <=8,5 % durante la selección.
    -Seguir un tratamiento antidiabético (sin incluir la insulina) que haya sido estable durante >=8 semanas antes de la primera visita de selección.
    8. Tratamiento con uno o más de los siguientes medicamentos de venta con o sin receta durante los seis meses previos a la primera visita de selección:
    -Medicamentos con propiedades androgénicas o estrogénicas o que afecten a la producción de hormonas sexuales.
    -Otros tratamientos de aumento de la testosterona.
    -Fármacos para la fertilidad.
    -Hormona del crecimiento.
    -Esteroides anabolizantes.
    -Anticuerpos monoclonales.
    9. Tratamiento con uno de los siguientes medicamentos en los tres meses previos a la primera visita de selección:
    -Fármacos reductores de la testosterona (p. ej., espironolactona, cimetidina, inhibidores de la 5?-reductasa).
    -Opiáceos, incluida la metadona.
    -Medicamentos que se sabe que aumentan los niveles de prolactina (p. ej., los antipsicóticos).
    -Insulina.
    10. Tratamiento con los siguientes medicamentos:
    -Tratamiento con corticoesteroides sistémicos crónico o durante >5 días consecutivos para una enfermedad intercurrente en las 4 semanas previas a la primera visita de selección (se permiten los corticoesteroides de uso externo o inhalados).
    -Nuevo medicamento de venta con o sin receta que afecte a la homeostasis de la glucosa en las 4 semanas previas a la primera visita de selección.
    -Clomifeno en el año previo a la primera visita de selección.
    -Bisfosfonatos u otros medicamentos utilizados para el tratamiento de la densidad ósea baja (denosumab, teriparatida), a excepción del calcio y la vitamina D en el año previo a la primera visita de selección.
    11. Pérdida o aumento de peso (pérdida o aumento de un porcentaje máximo del 5 % del peso corporal) en los 3 meses previos a la primera visita de selección.
    12. Participación en cualquier ensayo clínico en el que se utilizara una intervención clínica en los 3 meses previos a la primera visita de selección o 5 semividas de administración del producto experimental, lo que se produjera antes.
    13. Cualquier anomalía clínicamente significativa en el ECG de 12 derivaciones durante la selección, incluido el intervalo QT corregido mediante el método de corrección Fridericia (QTCF) >450 ms.
    14. Antecedentes médicos de síndrome del QT largo.
    15. Antecedentes de enfermedad tromboembólica.
    16. Edema en las extremidades inferiores de grado 3.
    17. Uso de un marcapasos cardíaco u otros dispositivos médicos electrónicos que puedan verse afectados por la evaluación de bioimpedancia.

    Véase en protocolo para consultar criterios de exclusión adicionales
    E.5 End points
    E.5.1Primary end point(s)
    1. Normalisation of total testosterone levels in ? 75% of subjects at Week 24.
    1.Normalización de los niveles de testosterona total en >=75 % de los pacientes en la semana 24
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    semana 24
    E.5.2Secondary end point(s)
    Secondary
    1. Proportion of subjects that have normalisation of total testosterone at Week 24
    2. Proportion of subjects that overshoot testosterone (total testosterone above 1000 ng/dL [35 nmol/L]) at Week 24
    3. Normalisation of total testosterone in ? 90% subjects at Week 24
    4. Change of LH and FSH at 24 weeks
    5. Population PK analysis of plasma BGS649 concentrations
    6. PK analysis of semen BGS649 concentrations.

    Exploratory
    1. Change in oestradiol, inhibins (A and B) levels and DHT
    2. Change in testosterone/oestradiol ratio
    3. Body composition changes at Week 12 and Week 24
    4. Changes in markers of cardiometabolic disease: blood pressure, lipid profile, HbA1c, glucose and insulin, hs-CRP and HOMA-IR
    5. Change in markers of bone turnover in those with and without 25 hydroxy vitamin D deficiency
    6. Change in PROs (Sexual function (IIEF) , Energy/fatigue (BFI), SF-36 QoL questionnaire) over the 24-week period
    7. Change in physical activity, sleeping pattern and strength measured by wrist worn monitors and grip strength measurement at 12 and 24 weeks
    8. PK/pharmacodynamic (PD) relationship between BGS649 concentrations and testosterone levels
    9. For semen analysis: change in semen parameters throughout the study
    10. Change in bioavailable testosterone
    11. Time to first normal testosterone level.

    Safety
    1. Treatment emergent AEs (TEAEs)/SAEs (from first dose of study drug until 90 days after last treatment dose)
    2. Change in PSA during 24 week treatment duration
    3. Change in haematocrit during 24 week treatment duration
    4. Change in Bone Mineral Density (DEXA scan T-score and density in g/cm3) from Screening and bone turnover biomarkers at 24-weeks from Baseline
    5. Change in vital signs and clinical laboratory parameters, ECG
    6. Change in physical examination (including general, prostate, breast and oedema of the lower extremities).
    Secundarios
    1.Proporción de pacientes que han logrado una normalización de la testosterona total en la semana 24.
    2.Proporción de pacientes que excedan el nivel de testosterona (testosterona total superior a 1000 ng/dl [35 nmol/l]) en la semana 24.
    3.Normalización de la testosterona total en >=90 % de los pacientes en la semana 24.
    4.Cambio de LH y FSH al cabo de 24 semanas.
    5.Análisis FC de la población para determinar las concentraciones de BGS649 en el plasma.
    6.Análisis FC de las concentraciones de BGS649 en el semen.
    Exploratorios
    1. Cambio en los niveles de estradiol, inhibinas (A y B) y DHT.
    2.Cambio en la tasa de testosterona/estradiol.
    3.Cambios en la composición corporal en la semana 12 y la semana 24.
    4.Cambios en los marcadores de enfermedad cardiometabólica: presión arterial, perfil lipídico, HbA1c, glucosa e insulina, hs-CRP y HOMA-IR.
    5.Cambio en los marcadores de recambio óseo en aquellos pacientes con o sin insuficiencia de 25-hidroxivitamina D.
    6.Cambio en los RNP (actividad sexual [IIEF], energía/astenia [BFI], cuestionario SF-36 sobre la calidad de vida) durante el período de 24 semanas.
    7.Cambio en la actividad física, los hábitos de sueño y la fuerza medido mediante monitores de pulsera y la medición de la fuerza de prensión al cabo de 12 y 24 semanas.
    8.Relación FC/farmacodinámica (FD) entre las concentraciones de BGS649 y los niveles de testosterona.
    9.Para el análisis del semen: cambio en los parámetros espermáticos a lo largo del estudio.
    10.Cambio en la testosterona biodisponible.
    11.Tiempo transcurrido hasta el primer nivel de testosterona normal.
    Seguridad
    1.AA asociados con el tratamiento (AAAT)/AAG (desde la primera dosis del fármaco del estudio hasta 90 días después de la última administración del tratamiento).
    2.Cambio en PSA durante las 24 semanas de tratamiento.
    3.Cambio en el hematocrito durante las 24 semanas de tratamiento.
    4.Cambio en la densidad mineral ósea (puntuación T en la DEXA y densidad en g/cm3) desde la selección y biomarcadores de recambio óseo al cabo de 24 semanas a partir del inicio del estudio.
    5.Cambio en las constantes vitales y los parámetros clínicos, ECG.
    6.Cambio en la exploración física (general, próstata, mama y edema en las extremidades inferiores)
    E.5.2.1Timepoint(s) of evaluation of this end point
    As per protocol
    Según el protocolo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Italy
    Spain
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 268
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 120
    F.4.2.2In the whole clinical trial 268
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety extension study (Protocol MBGS206).
    All other subjects - None
    Se invitará a algunos de los pacientes que completen las 24 semanas de tratamiento a participar en un estudio enmascarado de prolongación de seguridad de 6 meses (Protocolo MBGS206).

    El resto de pacientes: ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-07-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-06-06
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-05-03
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 13:19:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA